Nuwellis Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuwellis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Nuwellis stock.
View analyst ratings for Nuwellis or view top-rated stocks.

Wall Street analysts have given Nuwellis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nuwellis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Nuwellis, Inc. (NASDAQ:CHFS) posted its quarterly earnings data on Monday, March, 1st. The company reported ($1.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.91) by $0.34. The company earned $2.04 million during the quarter. Nuwellis had a negative trailing twelve-month return on equity of 173.61% and a negative net margin of 254.26%.
View Nuwellis' earnings history.

Shares of Nuwellis reverse split on the morning of Friday, October 13th 2017. The 1-20 reverse split was announced on Thursday, October 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 12th 2017. An investor that had 100 shares of Nuwellis stock prior to the reverse split would have 5 shares after the split.

1 analysts have issued 12 month price objectives for Nuwellis' shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Nuwellis' stock price to reach $20.00 in the next year. This suggests a possible upside of 341.5% from the stock's current price.
View analysts' price targets for Nuwellis or view top-rated stocks among Wall Street analysts.

Some companies that are related to Nuwellis include ENDRA Life Sciences (NDRA), Electromed (ELMD), Soleno Therapeutics (SLNO), electroCore (ECOR), Fc Global Realty (FCRE), Helius Medical Technologies (HSDT), Viveve Medical (VIVE), ReShape Lifesciences (RSLS), Nuwellis (NUWE), Precision Optics (PEYE), Star Equity (STRR), Vaso (VASO), Micron Solutions (MICR), ADM Tronics Unlimited (ADMT) and Guided Therapeutics (GTHP).
View all of CHFS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nuwellis investors own include Biocept (BIOC), Immutep (IMMP), Tonix Pharmaceuticals (TNXP), T2 Biosystems (TTOO), Zosano Pharma (ZSAN), Avinger (AVGR), Co-Diagnostics (CODX), iBio (IBIO), Inovio Pharmaceuticals (INO) and Onconova Therapeutics (ONTX).

Nuwellis trades on the NASDAQ under the ticker symbol "CHFS."

One share of CHFS stock can currently be purchased for approximately $4.53.

Nuwellis has a market capitalization of $27.35 million and generates $5.51 million in revenue each year. The company earns $-18,110,000.00 in net income (profit) each year or ($279.28) on an earnings per share basis.

Nuwellis employs 66 workers across the globe.

The official website for Nuwellis is www.chf-solutions.com.

Nuwellis is headquartered at 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN, 55344.

Nuwellis' mailing address is 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN, 55344. The company can be reached via phone at (952) 345-4200 or via email at [email protected]